Plant-based Biologics Market, by Product Type (Monoclonal Antibodies, Alpha Interferon, Glucocerebrosidase, Vaccines, and Others), by Source Type (Carrot, Tobacco Leaves, Rice Seeds, Alfalfa, and Others), by Disease Indication (Gaucher Disease, Tooth Deca

Plant-based Biologics Market, by Product Type (Monoclonal Antibodies, Alpha Interferon, Glucocerebrosidase, Vaccines, and Others), by Source Type (Carrot, Tobacco Leaves, Rice Seeds, Alfalfa, and Others), by Disease Indication (Gaucher Disease, Tooth Decay, Hepatitis, Lymphoma, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Plant-based biologics are biologic drugs that are manufactured by using plant molecular farming. They are also known as plant-made biologics (PMB). The applications and advantages of plant-based biologics have stretched beyond the traditional boundaries of vaccines and therapeutic proteins. For instance, bacterial colicins derived from plants in 2015 were recently proven effective as food additives for controlling pathogenic bacteria in food products. These colicins are highly effective (even when used in lower concentrations) to fight against all the pathogenic Escherichia coli strains that cause food poisoning. Moreover, it costs around US$ 1.00 for manufacturing one gram of purified colicins, which is commercially viable.
Market Dynamics
The increasing demand for biologics for various chronic diseases and rising investments in R&D for the production of biologics are expected to contribute significantly to the growth of plant-based biologics market. For instance, according to the Biotechnology Innovation Organization (BIO) 2015, over 250 biologic therapies and vaccines have changed the lives of hundreds of millions of patients. Moreover, according to the same source, over 900 biologics are currently (2018) under the stage of development for over 100 diseases in the U.S. Furthermore, according to the Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority of the investments was made by all the biopharmaceutical companies in the U.S. for the treatment of rare diseases.
Many biopharmaceutical companies are focused on developing plant-made pharmaceuticals using various plants such as tobacco, duckweed, moss, alfalfa, and other plants, which is expected to propel growth of the plant-based biologics market. For instance, in September 2015, LeafBio, Inc., the commercial partner of Mapp Biopharmaceutical, Inc. (Mapp), was granted fast track designation by the U.S. Food and Drug Administration (FDA) for their plant-made drug ZMapp for the treatment of Ebola virus disease.
However, stringent regulatory guidelines for the production of plant-based biologics is one of the major factors restraining growth of the plant-based biologics market. Moreover, concern regarding contamination and environmental risks is another factor restraining growth of the market.
Key features of the study:
This report provides in-depth analysis of the global plant-based biologics market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global plant-based biologics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., Eleva GmbH, Kentucky Bioprocessing, LLC, Solarvest Bioenergy Inc., and Byondis B.V.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global plant-based biologics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for plant-based biologics market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Plant-based Biologics Market, By Product Type:
Monoclonal Antibodies
Alpha Interferon
Glucocerebrosidase
Vaccines
Others
Global Plant-based Biologics Market, By Source Type:
Carrot
Tobacco Leaves
Rice Seeds
Alfalfa
Others
Global Plant-based Biologics Market, By Disease Indication:
Gaucher Disease
Tooth Decay
Hepatitis
Lymphoma
Others
Global Plant-based Biologics Market, By Region:
North America
By Country:
U.S.
Canada
By Product Type:
Monoclonal Antibodies
Alpha Interferon
Glucocerebrosidase
Vaccines
Others
By Source Type:
Carrot
Tobacco Leaves
Rice Seeds
Alfalfa
Others
By Disease Indication:
Gaucher Disease
Tooth Decay
Hepatitis
Lymphoma
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product Type:
Monoclonal Antibodies
Alpha Interferon
Glucocerebrosidase
Vaccines
Others
By Source Type:
Carrot
Tobacco Leaves
Rice Seeds
Alfalfa
Others
By Disease Indication:
Gaucher Disease
Tooth Decay
Hepatitis
Lymphoma
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product Type:
Monoclonal Antibodies
Alpha Interferon
Glucocerebrosidase
Vaccines
Others
By Source Type:
Carrot
Tobacco Leaves
Rice Seeds
Alfalfa
Others
By Disease Indication:
Gaucher Disease
Tooth Decay
Hepatitis
Lymphoma
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Monoclonal Antibodies
Alpha Interferon
Glucocerebrosidase
Vaccines
Others
By Source Type:
Carrot
Tobacco Leaves
Rice Seeds
Alfalfa
Others
By Disease Indication:
Gaucher Disease
Tooth Decay
Hepatitis
Lymphoma
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Monoclonal Antibodies
Alpha Interferon
Glucocerebrosidase
Vaccines
Others
By Source Type:
Carrot
Tobacco Leaves
Rice Seeds
Alfalfa
Others
By Disease Indication:
Gaucher Disease
Tooth Decay
Hepatitis
Lymphoma
Others
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Product Type:
Monoclonal Antibodies
Alpha Interferon
Glucocerebrosidase
Vaccines
Others
By Source Type:
Carrot
Tobacco Leaves
Rice Seeds
Alfalfa
Others
By Disease Indication:
Gaucher Disease
Tooth Decay
Hepatitis
Lymphoma
Others
Company Profiles
Leaf Expression Systems*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Zea Biosciences
Planet Biotechnology Inc.
InVitria
PlantForm Corporation
IBIO, Inc.
Mapp Biopharmaceutical, Inc.
Pfizer Inc.
Ventria Bioscience Inc.
Medicago Inc.
Eleva GmbH
Kentucky Bioprocessing, LLC
Solarvest Bioenergy Inc.
Byondis B.V.
“*” marked represents similar segmentation in other categories in the respective section.